Vitrolife First Third of STEEN Solution(TM) Study in USA Completed

BORG, Sweden--(BUSINESS WIRE)--Regulatory News: Vitrolife AB (publ) (STO:VITR): The fourth of the total of twelve patients included in the USA study for STEEN Solution™, and which enables sales approval in the important USA market, has now received a transplant. The first transplantation was carried out in September and four transplantations have thus now been carried out at four centres. A fifth centre, Duke University, has been included in the study, and it is anticipated that they will be able to start within approximately one month there.